Impact of tocilizumab administration on mortality in severe COVID-19

DOI record: { "DOI": "10.1038/s41598-020-76187-y", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-020-76187-y", "abstract": "<jats:title>Abstract</jats:title><jats:p>The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a significant burden on hospitals and healthcare providers. The immune response to this disease is thought to lead to an aberrant inflammatory response or cytokine storm, which contributes to the severity of illness. There is an urgent need to confirm whether the use of tocilizumab provides a benefit in individuals with COVID-19. A single-center propensity-score matched cohort study, including all consecutive COVID-19 patients, admitted to the medical center who were either discharged from the medical center or expired between March 1, 2020, and May 5, 2020, was performed. Patients were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls using propensity scores. The primary outcome was in-hospital mortality. A total of 274 patients meeting inclusion and exclusion criteria were identified and 132 patients were included in the matched dataset (tocilizumab = 66; no tocilizumab = 66). Approximately 73% of the patients were male. Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary disease (15%) were the most common comorbidities present. There were 18 deaths (27.3%) in the tocilizumab group and 18 deaths (27.3%) in the no tocilizumab group (odds ratio, 1.0; 95% confidence interval, 0.465 – 2.151; p = 1.00). Advanced age, history of myocardial infarction, dementia, chronic pulmonary disease, heart failure, and malignancy were significantly more common in patients who died. The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19. Use of this therapeutic agent should be limited to the context of a clinical trial until more evidence is available.</jats:p>", "alternative-id": [ "76187" ], "article-number": "19131", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "10 July 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "16 October 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "5 November 2020" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Tsai", "given": "Andrew", "sequence": "first" }, { "affiliation": [], "family": "Diawara", "given": "Oumou", "sequence": "additional" }, { "affiliation": [], "family": "Nahass", "given": "Ronald G.", "sequence": "additional" }, { "affiliation": [], "family": "Brunetti", "given": "Luigi", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 11, 5 ] ], "date-time": "2020-11-05T11:03:19Z", "timestamp": 1604574199000 }, "deposited": { "date-parts": [ [ 2022, 12, 6 ] ], "date-time": "2022-12-06T22:36:42Z", "timestamp": 1670366202000 }, "indexed": { "date-parts": [ [ 2024, 9, 2 ] ], "date-time": "2024-09-02T13:05:57Z", "timestamp": 1725282357011 }, "is-referenced-by-count": 42, "issue": "1", "issued": { "date-parts": [ [ 2020, 11, 5 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2020, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 11, 5 ] ], "date-time": "2020-11-05T00:00:00Z", "timestamp": 1604534400000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 11, 5 ] ], "date-time": "2020-11-05T00:00:00Z", "timestamp": 1604534400000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-020-76187-y.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-020-76187-y", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-020-76187-y.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2020, 11, 5 ] ] }, "published-online": { "date-parts": [ [ 2020, 11, 5 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.7150/ijbs.45134", "author": "Y Yi", "doi-asserted-by": "publisher", "first-page": "1753", "issue": "10", "journal-title": "Int. J. Biol. Sci.", "key": "76187_CR1", "unstructured": "Yi, Y., Lagniton, P. N. P., Ye, S., Li, E. & Xu, R. H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int. J. Biol. Sci. 16(10), 1753–1766 (2020).", "volume": "16", "year": "2020" }, { "DOI": "10.1016/j.jinf.2020.03.037", "author": "Q Ye", "doi-asserted-by": "publisher", "first-page": "607", "issue": "6", "journal-title": "J. Infect.", "key": "76187_CR2", "unstructured": "Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 80(6), 607–613 (2020).", "volume": "80", "year": "2020" }, { "DOI": "10.2147/ITT.S202015", "author": "H Murthy", "doi-asserted-by": "publisher", "first-page": "43", "journal-title": "Immunotargets Ther.", "key": "76187_CR3", "unstructured": "Murthy, H., Iqbal, M., Chavez, J. C. & Kharfan-Dabaja, M. A. Cytokine release syndrome: Current perspectives. Immunotargets Ther. 8, 43–52 (2019).", "volume": "8", "year": "2019" }, { "DOI": "10.1016/S0140-6736(20)30628-0", "author": "P Mehta", "doi-asserted-by": "publisher", "first-page": "1033", "issue": "10229", "journal-title": "Lancet", "key": "76187_CR4", "unstructured": "Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395(10229), 1033–1034 (2020).", "volume": "395", "year": "2020" }, { "DOI": "10.1007/s00134-020-05991-x", "doi-asserted-by": "crossref", "key": "76187_CR5", "unstructured": "Ruan, Q., Yang, K., Wang, W., Jiang, L., Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020)." }, { "DOI": "10.1016/S0140-6736(20)30566-3", "author": "F Zhou", "doi-asserted-by": "publisher", "first-page": "1054", "issue": "10229", "journal-title": "Lancet", "key": "76187_CR6", "unstructured": "Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395(10229), 1054–1062 (2020).", "volume": "395", "year": "2020" }, { "DOI": "10.1182/blood-2014-05-552729", "author": "DW Lee", "doi-asserted-by": "publisher", "first-page": "188", "issue": "2", "journal-title": "Blood", "key": "76187_CR7", "unstructured": "Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2), 188–195 (2014).", "volume": "124", "year": "2014" }, { "DOI": "10.1007/s00281-017-0629-x", "author": "R Channappanavar", "doi-asserted-by": "publisher", "first-page": "529", "issue": "5", "journal-title": "Semin. Immunopathol.", "key": "76187_CR8", "unstructured": "Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39(5), 529–539 (2017).", "volume": "39", "year": "2017" }, { "DOI": "10.1093/intimm/dxx031", "author": "KF Kernan", "doi-asserted-by": "publisher", "first-page": "401", "issue": "9", "journal-title": "Int. Immunol.", "key": "76187_CR9", "unstructured": "Kernan, K. F. & Carcillo, J. A. Hyperferritinemia and inflammation. Int. Immunol. 29(9), 401–409 (2017).", "volume": "29", "year": "2017" }, { "DOI": "10.1136/bmj.39335.541782.AD", "author": "E von Elm", "doi-asserted-by": "publisher", "first-page": "806", "issue": "7624", "journal-title": "BMJ", "key": "76187_CR10", "unstructured": "von Elm, E. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 335(7624), 806–808 (2007).", "volume": "335", "year": "2007" }, { "DOI": "10.1016/j.jaci.2020.05.008", "author": "T Herold", "doi-asserted-by": "publisher", "first-page": "128", "journal-title": "J. Allergy Clin. Immunol.", "key": "76187_CR11", "unstructured": "Herold, T. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 146, 128–136124. https://doi.org/10.1016/j.jaci.2020.05.008 (2020).", "volume": "146", "year": "2020" }, { "DOI": "10.1101/2020.04.20.20061861", "doi-asserted-by": "crossref", "key": "76187_CR12", "unstructured": "Roumier, M., Paule, R., Groh, M., Vallee, A., Ackermann, F. Interleukin-6 blockade for severe COVID-19. medRxiv. 2020:2020.04.20.20061861." }, { "DOI": "10.1073/pnas.2005615117", "doi-asserted-by": "crossref", "key": "76187_CR13", "unstructured": "Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U S A. (2020)." }, { "DOI": "10.1016/j.ijantimicag.2020.105954", "author": "C Zhang", "doi-asserted-by": "publisher", "first-page": "105954", "journal-title": "Int. J. Antimicrob. Agents.", "key": "76187_CR14", "unstructured": "Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents. 29, 105954 (2020).", "volume": "29", "year": "2020" }, { "DOI": "10.1001/jama.2020.6775", "doi-asserted-by": "crossref", "key": "76187_CR15", "unstructured": "Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, J.M., McGinn, T., Davidson, K.W., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. (2020)." }, { "DOI": "10.1183/13993003.01227-2020", "doi-asserted-by": "crossref", "key": "76187_CR16", "unstructured": "Guan, W.J., Liang, W.H., Zhao, Y., Liang, H.R., Chen, Z.S., Li, Y.M., et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. Eur. Respir. J. (2020)." }, { "DOI": "10.1007/s11357-020-00186-0", "doi-asserted-by": "crossref", "key": "76187_CR17", "unstructured": "Nikolich-Zugich, J., Knox, K.S., Rios, C.T., Natt, B., Bhattacharya, D., Fain, M.J. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. (2020)." }, { "DOI": "10.1101/2020.03.30.20048058", "doi-asserted-by": "crossref", "key": "76187_CR18", "unstructured": "Coomes, E.A., Haghbayan, H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. medRxiv. 2020:2020.03.30.20048058." }, { "key": "76187_CR19", "unstructured": "Gritti, G., Raimondi, F., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv. 2020:2020.04.01.20048561." }, { "DOI": "10.1056/NEJMe2015903", "doi-asserted-by": "crossref", "key": "76187_CR20", "unstructured": "Rubin, E.J., Harrington, D.P., Hogan, J.W., Gatsonis, C., Baden, L.R., Hamel, M.B. The urgency of care during the Covid-19 pandemic—Learning as we go. N. Engl. J. Med. (2020)." }, { "DOI": "10.1128/JVI.79.10.6441-6448.2005", "author": "N Schmitz", "doi-asserted-by": "publisher", "first-page": "6441", "issue": "10", "journal-title": "J. Virol.", "key": "76187_CR21", "unstructured": "Schmitz, N., Kurrer, M., Bachmann, M. F. & Kopf, M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 79(10), 6441–6448 (2005).", "volume": "79", "year": "2005" }, { "DOI": "10.1186/1465-9921-9-57", "author": "MD Tate", "doi-asserted-by": "publisher", "first-page": "57", "journal-title": "Respir. Res.", "key": "76187_CR22", "unstructured": "Tate, M. D., Brooks, A. G. & Reading, P. C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir. Res. 9, 57 (2008).", "volume": "9", "year": "2008" }, { "DOI": "10.1111/bcp.13500", "author": "C Bastida", "doi-asserted-by": "publisher", "first-page": "716", "issue": "4", "journal-title": "Br. J. Clin. Pharmacol.", "key": "76187_CR23", "unstructured": "Bastida, C. et al. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br. J. Clin. Pharmacol. 84(4), 716–725 (2018).", "volume": "84", "year": "2018" }, { "key": "76187_CR24", "unstructured": "Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients. https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-02-22-30-00. Accessed 8 Jul 2020." }, { "key": "76187_CR25", "unstructured": "Perrone, F., Piccirillo, M.C., Ascierto, P.A., Salvarani, C., Parrella, R., Marata, A.M., et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. medRxiv. 2020:2020.06.01.20119149." }, { "key": "76187_CR26", "unstructured": "Parodi E, O’Donnell C. Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study. https://www.reuters.com/article/us-health-coronavirus-roche-hldg/roche-rheumatoid-arthritis-drug-fails-to-help-covid-19-patients-in-italian-study-idUSKBN23O3GG/. Published 17 June 2020. Accessed 18 June 2020." }, { "key": "76187_CR27", "unstructured": "National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ Accessed 7 May 2020." } ], "reference-count": 27, "references-count": 27, "relation": { "has-preprint": [ { "asserted-by": "object", "id": "10.1101/2020.07.30.20114959", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-020-76187-y" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Impact of tocilizumab administration on mortality in severe COVID-19", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "10" }